Carboplatin and Pegfilgrastim-jmdb Subcutaneous

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using pegfilgrastim before, during, or too soon after completion of a course of CARBOplatin may alter the effects of either medication. Pegfilgrastim should generally not be given from 14 days before until 24 hours after cancer chemotherapy. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.

MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.

Carboplatin

Generic Name: carboplatin

Brand name: Paraplatin, CARBOplatin Novaplus

Synonyms: CARBOplatin

What is Carboplatin?

Pegfilgrastim-jmdb Subcutaneous

Generic Name: pegfilgrastim

Brand name: Fulphila, Neulasta, Neulasta Onpro Kit, Udenyca, Neulasta Delivery Kit

Synonyms: Pegfilgrastim

What is Pegfilgrastim-jmdb Subcutaneous?